Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(14%)
Results Posted
20%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
5
71%
Ph phase_2
1
14%
Ph phase_3
1
14%

Phase Distribution

5

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (71.4%)
Phase 21 (14.3%)
Phase 31 (14.3%)

Trials by Status

active_not_recruiting114%
completed571%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_1

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT04616248
completedphase_2

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075
completedphase_1

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

NCT00020540
completedphase_3

flt3L in Treating Patients With Acute Myeloid Leukemia

NCT00006223
completedphase_1

Flt3L in Treating Patients With Metastatic Colorectal Cancer

NCT00003431
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04616248Phase 1

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Active Not Recruiting
NCT02129075Phase 2

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Completed
NCT00020540Phase 1

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Completed
NCT00006223Phase 3

flt3L in Treating Patients With Acute Myeloid Leukemia

Completed
NCT00003431Phase 1

Flt3L in Treating Patients With Metastatic Colorectal Cancer

Completed
NCT00006225Phase 1

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Completed
NCT00005787Phase 1

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Terminated

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7